Experienced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Kerry P. Pulver

Hematology Oncology | Oncology | Hematology
Saint Alphonsus Regional Medical Center Inc
4400 E Flamingo Ave, 
Nampa, ID 
Accepting New Patients
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
Saint Alphonsus Regional Medical Center Inc
4400 E Flamingo Ave, 
Nampa, ID 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kerry Pulver is a Hematologist Oncology specialist and an Oncologist in Nampa, Idaho. Dr. Pulver is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer. Dr. Pulver is currently accepting new patients.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in ID
Hospital Affiliations
Saint Alphonsus Regional Medical Center
St Luke's Regional Medical Center
Saint Alphonsus Medical Center - Nampa
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

SAINT ALPHONSUS REGIONAL MEDICAL CENTER INC
4400 E Flamingo Ave, Nampa, ID 83687
Other Locations
SAINT ALPHONSUS REGIONAL MEDICAL CENTER INC
3123 Medical Dr, Caldwell, ID 83605
SAINT ALPHONSUS REGIONAL MEDICAL CENTER INC
3025 W Cherry Ln, Meridian, ID 83642
SAINT ALPHONSUS REGIONAL MEDICAL CENTER INC
1055 N Curtis Rd, Boise, ID 83706

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: X-396 (Ensartinib), Crizotinib
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Enrollment Status: Completed
Publish Date: March 22, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Enrollment Status: Terminated
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials
Similar Doctors
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Travis G. Williams
Oncology | Hematology Oncology | Hematology
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Travis G. Williams
Oncology | Hematology Oncology | Hematology

St Lukes Clinic-Treasure Valley LLC

100 E Bannock St, 
Boise, ID 
 (16.2 miles away)
208-381-2983
Languages Spoken:
English, Portugese, Spanish
See accepted insurances
Accepting New Patients

Travis Williams is an Oncologist and a Hematologist Oncology provider in Boise, Idaho. Dr. Williams is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Williams is currently accepting new patients.

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. William H. Kreisle
Hematology Oncology | Hematology | Oncology
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. William H. Kreisle
Hematology Oncology | Hematology | Oncology

St Lukes Clinic-Treasure Valley LLC

100 E Bannock St, 
Boise, ID 
 (16.2 miles away)
208-381-2983
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Kreisle is a Hematologist Oncology specialist and a Hematologist in Boise, Idaho. Dr. Kreisle is rated as an Advanced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Kreisle is currently accepting new patients.

Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Silvana Bucur
Oncology | Hematology Oncology
Advanced in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Silvana Bucur
Oncology | Hematology Oncology

St Lukes Clinic-Treasure Valley LLC

520 S Eagle Rd, 
Meridian, ID 
 (8.3 miles away)
Languages Spoken:
English
See accepted insurances

Silvana Bucur is an Oncologist and a Hematologist Oncology provider in Meridian, Idaho. Dr. Bucur is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Inflammatory Breast Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pulver's expertise for a condition
ConditionClose
    View All 94 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile